Novartis Stops Late-Stage Trial of Remibrutinib for Lack of Efficacy
Novartis said it stopped a late-stage trial of remibrutinib in a rare neuromuscular disease due to lack of efficacy.
By Adria CalatayudNovartis said it stopped a late-stage clinical trial for its remibrutinib drug in a rare neuromuscular disease due to lack of efficacy, but executives said the medicine could still become the biggest in the company's history.The Swiss drugmaker disclosed the discontinuation of the…